Cover Image
市場調查報告書

鐮形血球貧血症:開發中產品分析

Sickle Cell Disease - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213124
出版日期 內容資訊 英文 190 Pages
訂單完成後即時交付
價格
Back to Top
鐮形血球貧血症:開發中產品分析 Sickle Cell Disease - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 190 Pages
簡介

鐮狀細胞貧血症為遺傳性(先天性)的血液疾病,血液中的紅血球形狀異常。主要的前兆、症狀為貧血和發育遲緩、視野障礙、疼痛、頻繁感染感染疾病等。主要的治療方法,有抗生素和止痛藥、輸血、幹細胞移植等。

本報告提供全球各國治療鐮形血球貧血症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

鐮形血球貧血症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

鐮形血球貧血症:企業開發中的治療藥

鐮形血球貧血症:大學/機關研究中的治療藥

鐮形血球貧血症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

鐮形血球貧血症:企業開發中的產品

鐮形血球貧血症:大學/機關研究中的產品

鐮形血球貧血症的治療藥開發企業

  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • Advinus Therapeutics Ltd.
  • Alnylam Pharmaceuticals, Inc.
  • BioAegis Therapeutics, Inc.
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Complexa, Inc.
  • CSL Limited
  • Dilaforette AB
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • Errant Gene Therapeutics, LLC
  • Gamida Cell Ltd.
  • Gilead Sciences, Inc.
  • Global Blood Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • La Jolla Pharmaceutical Company
  • Merck & Co., Inc.
  • Morphogenesis, Inc.
  • NKT Therapeutics, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Prolong Pharmaceuticals, LLC
  • ReveraGen BioPharma, Inc.
  • Sancilio & Company, Inc.
  • Sangamo BioSciences, Inc.
  • Sanofi

鐮形血球貧血症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

鐮形血球貧血症:最近的開發平台趨勢

鐮形血球貧血症:暫停中的計劃

鐮形血球貧血症:開發中止的產品

鐮形血球貧血症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9801IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H2 2017, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 4, 11, 25, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sickle Cell Disease - Overview
    • Sickle Cell Disease - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Sickle Cell Disease - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sickle Cell Disease - Companies Involved in Therapeutics Development
    • Acceleron Pharma Inc
    • Addmedica SAS
    • Angiocrine Bioscience Inc
    • Annexin Pharmaceuticals AB
    • ArQule Inc
    • Bio Products Laboratory Ltd
    • Bioverativ Inc
    • bluebird bio Inc
    • Bristol-Myers Squibb Co
    • Calimmune Inc
    • CRISPR Therapeutics
    • CSL Ltd
    • Daiichi Sankyo Co Ltd
    • Editas Medicine Inc
    • Errant Gene Therapeutics LLC
    • Gamida Cell Ltd
    • Genethon SA
    • Gilead Sciences Inc
    • Global Blood Therapeutics Inc
    • Incyte Corp
    • Ironwood Pharmaceuticals Inc
    • La Jolla Pharmaceutical Company
    • MaxCyte Inc
    • Merck & Co Inc
    • Morphogenesis Inc
    • NKT Therapeutics Inc
    • Novartis AG
    • Orphagen Pharmaceuticals Inc
    • Prolong Pharmaceuticals LLC
    • Protagonist Therapeutics Inc
    • ReveraGen BioPharma Inc
    • Sancilio & Company Inc
    • Sangamo Therapeutics Inc
    • Sickle Cell Disease - Drug Profiles
    • (decitabine + tetrahydrouridine) - Drug Profile
    • AB-110 - Drug Profile
    • ACY-957 - Drug Profile
    • ambrisentan - Drug Profile
    • AP-01 - Drug Profile
    • apixaban - Drug Profile
    • ARQ-092 - Drug Profile
    • BB-305 - Drug Profile
    • benserazide - Drug Profile
    • BIVV-003 - Drug Profile
    • CAL-H - Drug Profile
    • CordIn - Drug Profile
    • crizanlizumab - Drug Profile
    • CTX-001 - Drug Profile
    • didox - Drug Profile
    • Drugs to Inhibit PRMT5 for Sickle Cell Anemia - Drug Profile
    • DRX-194 - Drug Profile
    • GBT-440 - Drug Profile
    • Gene Therapy for Sickle Cell Anemia - Drug Profile
    • Gene Therapy for Sickle Cell Disease - Drug Profile
    • Gene Therapy for Sickle Cell Disease - Drug Profile
    • Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile
    • Gene Therapy to Activate Gamma Globin for Sickle Cell Disease - Drug Profile
    • Gene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia - Drug Profile
    • haptoglobin (human) - Drug Profile
    • haptoglobin + hemopexin - Drug Profile
    • HBI-002 - Drug Profile
    • HBI-137 - Drug Profile
    • hydroxyurea - Drug Profile
    • hydroxyurea - Drug Profile
    • IMR-687 - Drug Profile
    • INCB-59872 - Drug Profile
    • IW-1701 - Drug Profile
    • LJPC-401 - Drug Profile
    • luspatercept - Drug Profile
    • M-012 - Drug Profile
    • NiCord - Drug Profile
    • NKTT-120 - Drug Profile
    • panobinostat - Drug Profile
    • pentosan polysulfate sodium - Drug Profile
    • Polysaccharide to Inhibit Coagulation Factor X for Deep Vein Thrombosis and Sickle Cell Disease - Drug Profile
    • prasugrel hydrochloride - Drug Profile
    • Protein for Sickle Cell Disease - Drug Profile
    • PTG-300 - Drug Profile
    • RCY-1497 - Drug Profile
    • RN-1 - Drug Profile
    • RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile
    • Sanguinate - Drug Profile
    • SC-411 - Drug Profile
    • SCD-101 - Drug Profile
    • SCPF - Drug Profile
    • Small Molecules for Sickle Cell Disease - Drug Profile
    • Small Molecules for Sickle Cell Disease - Drug Profile
    • Small Molecules to Inhibit HDAC for Oncology and Sickle Cell Disease - Drug Profile
    • Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile
    • sotatercept - Drug Profile
    • Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile
    • Stem Cell Therapy to Activate Beta Globin for Sickle Cell Disease - Drug Profile
    • Trichosic - Drug Profile
    • vamorolone - Drug Profile
  • Sickle Cell Disease - Dormant Projects
  • Sickle Cell Disease - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Sickle Cell Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Sickle Cell Disease - Pipeline by Acceleron Pharma Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Addmedica SAS, H2 2017
  • Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H2 2017
  • Sickle Cell Disease - Pipeline by ArQule Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Bio Products Laboratory Ltd, H2 2017
  • Sickle Cell Disease - Pipeline by Bioverativ Inc, H2 2017
  • Sickle Cell Disease - Pipeline by bluebird bio Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Sickle Cell Disease - Pipeline by Calimmune Inc, H2 2017
  • Sickle Cell Disease - Pipeline by CRISPR Therapeutics, H2 2017
  • Sickle Cell Disease - Pipeline by CSL Ltd, H2 2017
  • Sickle Cell Disease - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
  • Sickle Cell Disease - Pipeline by Editas Medicine Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H2 2017
  • Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H2 2017
  • Sickle Cell Disease - Pipeline by Genethon SA, H2 2017
  • Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Incyte Corp, H2 2017
  • Sickle Cell Disease - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
  • Sickle Cell Disease - Pipeline by La Jolla Pharmaceutical Company, H2 2017
  • Sickle Cell Disease - Pipeline by MaxCyte Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Merck & Co Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Morphogenesis Inc, H2 2017
  • Sickle Cell Disease - Pipeline by NKT Therapeutics Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Novartis AG, H2 2017
  • Sickle Cell Disease - Pipeline by Orphagen Pharmaceuticals Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
  • Sickle Cell Disease - Pipeline by Protagonist Therapeutics Inc, H2 2017
  • Sickle Cell Disease - Pipeline by ReveraGen BioPharma Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Sancilio & Company Inc, H2 2017
  • Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H2 2017
  • Sickle Cell Disease - Dormant Projects, H2 2017
  • Sickle Cell Disease - Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Sickle Cell Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top